BBIO Stock Recent News

BBIO LATEST HEADLINES

BBIO Stock News Image - accesswire.com

NEW YORK, NY / ACCESSWIRE / July 14, 2024 / Pomerantz LLP is investigating claims on behalf of investors of BridgeBio Pharma, Inc. ("BridgeBio" or the "Company") (NASDAQ:BBIO). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.

accesswire.com 2024 Jul 14
BBIO Stock News Image - globenewswire.com

NEW YORK, July 07, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of BridgeBio Pharma, Inc. (“BridgeBio” or the “Company”) (NASDAQ: BBIO).   Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com  or 646-581-9980, ext. 7980.

globenewswire.com 2024 Jul 07
BBIO Stock News Image - globenewswire.com

PALO ALTO, Calif., July 05, 2024 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a commercial-stage biopharmaceutical company focused on genetic diseases, today announced that on July 2, 2024, the compensation committee of BridgeBio's board of directors approved equity grants to 25 new employees in restricted stock units for an aggregate of 123,070 shares of the Company's common stock. One-fourth of the shares underlying each employee's restricted stock units will vest on August 16, 2025, with one-twelfth of the remaining shares underlying each such employee's restricted stock units vesting on a quarterly basis thereafter, in each case, subject to each such employee's continued employment with the Company or one of its subsidiaries on such vesting dates. All of the above-described awards were made under BridgeBio's Amended and Restated 2019 Inducement Equity Plan (the “Plan”).

globenewswire.com 2024 Jul 05
BBIO Stock News Image - accesswire.com

NEW YORK, NY / ACCESSWIRE / July 5, 2024 / Pomerantz LLP is investigating claims on behalf of investors of BridgeBio Pharma, Inc. ("BridgeBio" or the "Company") (NASDAQ:BBIO). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.

accesswire.com 2024 Jul 05
BBIO Stock News Image - globenewswire.com

NEW YORK, June 30, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of BridgeBio Pharma, Inc. (“BridgeBio” or the “Company”) (NASDAQ: BBIO).   Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com  or 646-581-9980, ext. 7980.

globenewswire.com 2024 Jun 30
BBIO Stock News Image - prnewswire.com

NEW YORK , June 24, 2024 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of BridgeBio Pharma, Inc. ("BridgeBio" or the "Company") (NASDAQ: BBIO). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.

prnewswire.com 2024 Jun 24
BBIO Stock News Image - accesswire.com

NEW YORK, NY / ACCESSWIRE / June 24, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of BridgeBio Pharma, Inc. ("BridgeBio") (NASDAQ:BBIO) concerning possible violations of federal securities laws. BridgeBio issued a press release on June 4, 2024, "announc[ing] sustained positive results from PROPEL 2, a Phase 2 trial of the investigational therapy infigratinib in children with achondroplasia, demonstrating continued potential best-in-class efficacy and an encouraging safety profile.

accesswire.com 2024 Jun 24
BBIO Stock News Image - accesswire.com

NEW YORK, NY / ACCESSWIRE / June 22, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of BridgeBio Pharma, Inc. ("BridgeBio") (NASDAQ:BBIO) concerning possible violations of federal securities laws. BridgeBio issued a press release on June 4, 2024, "announc[ing] sustained positive results from PROPEL 2, a Phase 2 trial of the investigational therapy infigratinib in children with achondroplasia, demonstrating continued potential best-in-class efficacy and an encouraging safety profile.

accesswire.com 2024 Jun 22
BBIO Stock News Image - accesswire.com

NEW YORK, NY / ACCESSWIRE / June 22, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of BridgeBio Pharma, Inc. ("BridgeBio") (NASDAQ:BBIO) concerning possible violations of federal securities laws. BridgeBio issued a press release on June 4, 2024, "announc[ing] sustained positive results from PROPEL 2, a Phase 2 trial of the investigational therapy infigratinib in children with achondroplasia, demonstrating continued potential best-in-class efficacy and an encouraging safety profile.

accesswire.com 2024 Jun 22
BBIO Stock News Image - globenewswire.com

NEW YORK, June 22, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of BridgeBio Pharma, Inc. (“BridgeBio” or the “Company”) (NASDAQ: BBIO).   Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com  or 646-581-9980, ext. 7980.

globenewswire.com 2024 Jun 22
10 of 50